Insulet (PODD) Tops Q2 EPS by 9c, Lifts Revenue Guidance

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.08), $0.09 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $87.3 million versus the consensus estimate of $81.1 million.

GUIDANCE:

Insulet sees Q3 2016 revenue of $88-91 million, versus the consensus of $87 million.

Insulet sees FY2016 revenue of $345-355 million, versus the consensus of $343.6 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
• Lucid reports Q2 output, names new CFO and five other leaders
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan